Chang Shen-Shong, Hu Hsiao-Yun
From the Division of Gastroenterology (S-SC), Department of Internal Medicine, Taipei City Hospital Yang-Ming Branch; School of Medicine (S-SC); Institute of Public Health & Department of Public Health (H-YH), National Yang-Ming University; and Department of Education and Research (H-YH), Taipei City Hospital, Taipei, Taiwan.
Medicine (Baltimore). 2015 Jan;94(1):e370. doi: 10.1097/MD.0000000000000370.
End-stage renal disease (ESRD) patients exhibit an increased incidence of peptic ulcer disease. Helicobacter pylori plays a central role in the development of peptic ulcers. The effect of early H pylori eradication on the recurrence of complicated peptic ulcer disease in ESRD patients remains unclear. The aim of the present study was to explore whether early H pylori eradication therapy in ESRD patients can reduce the risk of recurrent complicated peptic ulcers.We conducted a population-based cohort study and recruited patients with ESRD who had developed peptic ulcers. We categorized patients into early (time lag ≦120 days after peptic ulcer diagnosis) and late H pylori eradication therapy groups. The Cox proportional hazards model was used. The endpoint was based on hospitalization for complicated recurrent peptic ulcers.The early and late H pylori eradication therapy groups consisted of 2406 and 1356 ESRD patients, respectively, in a time lag of 120 days. After adjusting for possible confounders, the early eradication group exhibited a lower rate of complicated recurrent peptic ulcer disease (hazard ratio [HR] = 0.76, 95% confidence interval [CI] = 0.64-0.91, P = 0.003) in a time lag of ≦120 days, but a similar rate of complicated recurrent peptic ulcer disease in time lags of ≦1 year (HR = 0.97, 95% CI 0.79-1.19, P = 0.758) and 2 years (HR = 1.11, 95% CI 0.86-1.44, P = 0.433) compared with the late eradication group.We recommend administering H pylori eradication within 120 days after peptic ulcer diagnosis to H pylori infected ESRD patients who have developed peptic ulcers.
终末期肾病(ESRD)患者消化性溃疡疾病的发病率增加。幽门螺杆菌在消化性溃疡的发生发展中起核心作用。早期根除幽门螺杆菌对ESRD患者复杂性消化性溃疡疾病复发的影响尚不清楚。本研究的目的是探讨ESRD患者早期根除幽门螺杆菌治疗是否能降低复发性复杂性消化性溃疡的风险。我们进行了一项基于人群的队列研究,招募了患有消化性溃疡的ESRD患者。我们将患者分为早期(消化性溃疡诊断后时间间隔≤120天)和晚期幽门螺杆菌根除治疗组。使用Cox比例风险模型。终点基于复发性复杂性消化性溃疡的住院情况。早期和晚期幽门螺杆菌根除治疗组分别有2406例和1356例ESRD患者,时间间隔为120天。在调整可能的混杂因素后,早期根除组在时间间隔≤120天时复发性复杂性消化性溃疡疾病的发生率较低(风险比[HR]=0.76,95%置信区间[CI]=0.64-0.91,P=0.003),但在时间间隔≤1年(HR=0.97,95%CI 0.79-1.19,P=0.758)和2年(HR=1.11,95%CI 0.86-1.44,P=0.433)时与晚期根除组相比复发性复杂性消化性溃疡疾病的发生率相似。我们建议对已发生消化性溃疡的幽门螺杆菌感染的ESRD患者在消化性溃疡诊断后120天内进行幽门螺杆菌根除治疗。